Lipid Nanoparticles Outperform Electroporation in Delivering Therapeutic HPV DNA Vaccines.
Ontology highlight
ABSTRACT: Therapeutic HPV vaccines that induce potent HPV-specific cellular immunity and eliminate pre-existing infections remain elusive. Among various candidates under development, those based on DNA constructs are considered promising because of their safety profile, stability, and efficacy. However, the use of electroporation (EP) as a main delivery method for such vaccines is notorious for adverse effects like pain and potentially irreversible muscle damage. Moreover, the requirement for specialized equipment adds to the complexity and cost of clinical applications. As an alternative to EP, lipid nanoparticles (LNPs) that are already commercially available for delivering mRNA and siRNA vaccines are likely to be feasible. Here, we have compared three intramuscular delivery systems in a preclinic
SUBMITTER: Li M
PROVIDER: S-EPMC11209142 | biostudies-literature | 2024 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA